Longevity Digest, October 4–11: the first human readout from a reprogramming therapy, and what Alzheimer's drugs actually buy
In the week of October 4–11, 2026: the first human data from an epigenetic-reprogramming therapy tested in glaucoma, an accounting of what the decades-old Alzheimer's drugs actually buy, the blueberry dose that held up in a randomized trial, and a protein target two of the four voices shared.
This digest covers the public output of Peter Attia, David Sinclair, Bryan Johnson's Blueprint team, and Rhonda Patrick between October 4 and October 11, 2026, Pacific Time. The week's largest single item is a first: Life Biosciences reported the earliest human data from ER-100, the epigenetic-reprogramming therapy it is testing in glaucoma, and the readout is a safety result from three patients, with efficacy still untested. Peter Attia spent his week on two questions about what a treatment actually delivers — what a pregnancy reveals about a woman's long-term risk, and how much the decades-old Alzheimer's drugs really buy. Rhonda Patrick argued the case for one cup of blueberries a day and explained why she leaves the banana out of the smoothie. Blueprint published a protein target, and the week's one cross-expert overlap lands on exactly that.
The week in one screen
| Figure | Focus this week | Primary evidence tier | Actionable takeaway |
|---|---|---|---|
| Peter Attia | Pregnancy as a cardiometabolic stress test 1; what cholinesterase inhibitors buy 2 | One clinical review episode; one pooled analysis of Cochrane reviews | The symptomatic Alzheimer's drugs beat placebo by about 2–3 points on a 70-point scale, near the lower end of what counts as clinically meaningful 2 |
| Bryan Johnson / Blueprint | A protein target, with sources and links to the store 3 | Company content built on population analyses | 1.2–1.6 grams of protein per kilogram of body weight a day, tilted toward plant sources 3 |
| Rhonda Patrick | One cup of blueberries a day 4; why she skips the banana 5 | A six-month randomized trial in adults with metabolic syndrome; feeding and mechanistic studies | One cup a day improved endothelial function in that trial; half a cup left it unchanged 6 |
| David Sinclair | First-in-human data from ER-100 in glaucoma 7 | An open-label Phase I safety readout in three patients | Two of three patients improved on visual-field testing; the trial was built for safety 8 |
Peter Attia: pregnancy as a stress test, and what Alzheimer's drugs actually buy
Peter Attia is a physician, the founder of the Early Medical practice, and the host of The Peter Attia Drive. He published twice in the window.
Pregnancy as a woman's earliest cardiometabolic stress test
Attia's October 5 episode is a conversation with Dr. Kathryn Gray, a physician-scientist and high-risk obstetrician who is an associate professor of obstetrics and gynecology and the division chief of maternal-fetal medicine at the University of Washington School of Medicine 1. Gray supplies the episode's frame: pregnancy is a stress test. Blood volume expands sharply, and insulin resistance climbs through the second half, so the body runs a cardiovascular and a metabolic challenge at once 1.
That stress test continues past delivery. A pregnancy complication can flag a predisposition to disease later in life, and that thread runs through the whole conversation. The episode works through how gestational diabetes is screened for and treated, the biology and management of preeclampsia, HELLP syndrome, and postpartum depression, then labor and delivery, stillbirth, and the growing use of cell-free DNA in prenatal screening 1. It also covers prenatal nutrition and folate, breastfeeding, and exercise during pregnancy.
Gray's specialty is the genetics of adverse pregnancy outcomes, so the long-term-health question is hers as much as Attia's 1. The free page carries the full topic list and the opening sections of the conversation; the detailed show notes sit behind the membership paywall, so the specific thresholds and screening intervals stay with the source.
What cholinesterase inhibitors actually buy
Attia's October 10 article, written with Taylor Yeater and Nicholas Nelson, is free, short, and answers a question patients and families ask directly: how much do the standard Alzheimer's drugs help 2? The drugs are cholinesterase inhibitors — donepezil, galantamine, and rivastigmine — which slow the breakdown of acetylcholine so that the signaling left in a damaged brain lasts longer 2.
The numbers are the point. Across a Cochrane review that pooled five trials and more than 1,100 patients, donepezil scored 2.67 points better than placebo on the Alzheimer's Disease Assessment Scale–Cognitive Subscale after about six months; rivastigmine was 1.79 points better, and galantamine 2.86 2. The scale runs from 0 to 70, where a cognitively normal older adult scores around 5 and someone with mild-to-moderate Alzheimer's often scores in the 20s or 30s 2. A single point is small: roughly one more word recalled from a 10-word list, or one more orientation detail named.
Estimates of the smallest change a patient or clinician would notice cluster around 3 to 4 points in mild Alzheimer's, which places the class average at the lower edge of that band 2. The article adds a caveat that changes how the number should be read: much of the two-to-three-point gap comes from the untreated group declining, while the treated group improved little 2. The drugs may be holding function that would otherwise be lost. The benefit also looks temporary: after a six-week washout of donepezil, previously treated patients were indistinguishable from those on placebo 2.
The practical conclusion is measured. The benefit is symptomatic and modest, side effects are usually manageable (in the pooled donepezil trials, 11% of the treated group stopped for adverse events against 7% on placebo), and a patient who tolerates the drug may reasonably keep taking it for whatever function it preserves 2. Stopping makes sense when the side effects or the burden outweigh an effect of that size.
David Sinclair: the first human readout from ER-100
David Sinclair is a professor of genetics at Harvard Medical School, the author of Lifespan, and the chairman of the board of Life Biosciences, the company running the trial below.
Three patients, 56 days, two visual fields
On October 8, Life Biosciences announced the first human data from the Phase I trial of ER-100, its epigenetic-restoration gene therapy for optic neuropathies, presented at the Eyecelerator meeting 78. ER-100 delivers three genes — OCT4, SOX2, and KLF4, together called OSK — in a single injection into the eye, with expression switched on by eight weeks of daily oral doxycycline 8.
Three participants with open-angle glaucoma received the lowest dose, 200 billion viral genomes. All three tolerated it through Day 56 with no dose-limiting toxicities, no serious adverse events, and no adverse events of special interest; the reported problems were tied to the injection itself, the steroid used to damp the immune response, or pre-existing conditions 8. Two of the three showed improvement on Humphrey visual-field testing, with more than 4 decibels of improvement at 28% or more of the tested points 8. A data safety board then cleared the trial to move to a dose three times higher 9.
The boundaries deserve the same attention as the result. This was an open-label Phase I study of three people with no control group, at a dose below the one planned next, and it was designed to test safety rather than whether sight can be restored 9. An industry readout notes that establishing efficacy will take more data 8. Sinclair, who chairs the company's board, called the news "an encouraging first step in epigenetic age restoration" and said he is waiting on more data as the safety trial continues 9. The background runs further back than this window: the same OSK approach improved vision in mice with glaucoma in a 2020 Nature paper from Sinclair's lab, was extended in non-human primates, and entered this first-in-human trial in 2026 910.
Two research signals from his feed
Sinclair's two most recent posts, both from October 11, amplify published work elsewhere. The first flags a Nature Aging paper reporting that lipid chains grow longer with age across mice, worms, flies, and humans, and that reversing that lengthening in the worm C. elegans by targeting the enzyme Plb1 extended lifespan 1112. Sinclair highlights that rapamycin, calorie restriction, and exercise reverse the trend in the authors' data. This is preclinical work, and the paper proposes lipid chain length as a research target.
The second post is a cell-level result: prolonged exposure to tadalafil, the drug sold as Cialis, promoted muscle-cell growth in the study Sinclair cites, which he offers as a possible explanation for the drug's association with better lean mass in people 13. A finding in cultured cells is a hypothesis about a mechanism, and the human lean-mass claim needs a trial to test it.
Blueprint: a protein number, and another bowl
Blueprint, Bryan Johnson's protocol company, published twice, both under staff bylines rather than a personal one from Johnson.
Protein for longevity, with a dose
Blueprint's October 5 article sets out a protein target and the case for it 3. The recommendation is 1.2–1.6 grams of protein per kilogram of body weight per day, with somewhat more for people training for muscle growth. For longevity specifically, the page leans on an analysis of 63 studies linking higher protein intake to lower all-cause mortality, with plant proteins associated with lower risk again — an extra 3% of daily energy from plant protein was tied to a 5% lower risk of death from any cause 3. The suggested sources are eggs, nuts and seeds, unsweetened yogurt, lean poultry, legumes, and fatty fish, with processed and fatty red meats played down.
Two things are worth separating when reading it. The intake figures come from observational research on populations, where the link is an association 3. And the article's product links, including a protein powder, route back to Blueprint's store, so the page serves as a summary and a shop page at once 3.
One line on the longevity bowl
The second Blueprint item, from October 8, is a recipe: a bowl built from sweet potato, asparagus, kale, red pepper, carrots, walnuts, white beans, and herbs, coming to roughly 390 calories and 14 grams of protein per serving 14. It follows the pattern this blog has kept for months, presenting what Johnson eats as something a reader can copy.
Rhonda Patrick: one cup of blueberries, and a members' Q&A
Rhonda Patrick is a biomedical scientist and the host of the FoundMyFitness podcast. She published a solo episode, a members' Q&A, and a run of posts tied to both.
One cup, not half
Her October 6 episode works through the human evidence on blueberries and lands on a simple dose: about one cup of whole fresh or frozen berries a day 4. The strongest signal is vascular. In a six-month, double-blind, randomized trial in adults with metabolic syndrome, a daily intake equivalent to one cup of blueberries improved flow-mediated dilation — how well an artery widens when blood flow rises — while the half-cup dose left it unchanged 6. Patrick returns to that dose-response repeatedly, because it makes the dose itself the finding 4.
The cognitive evidence is observational and comes with its own shape. She cites the Nurses' Health Study, where older women who ate at least half a cup of blueberries a week showed slower cognitive decline than women who ate them rarely 1516. A cup of blueberries supplies roughly 160 to 385 milligrams of anthocyanins, the pigment class most of the vascular work has studied 4. Throughout, Patrick draws a line between effects measured on surrogates — artery function, blood markers, gene expression — and effects on outcomes a person would notice, and she keeps most of the metabolic benefit in the second group only when the system is already under strain, as in insulin resistance 4.
Why she leaves the banana out
The episode's most quotable result needs to be quoted carefully, and Patrick does that work herself. Bananas carry high levels of polyphenol oxidase, an enzyme that browns the fruit and also breaks down polyphenols, so she blends avocado into her blueberry smoothie instead 5. In the study she walks through, a banana smoothie carried about 93 times the polyphenol-oxidase activity of a mixed-berry smoothie, and the peak blood level of epicatechin-derived metabolites fell 84% and six-hour exposure fell 81% after it; even sipping the banana and the drink separately cut exposure 37% 4.
Then the correction. That 84% figure describes epicatechin, mostly from a cocoa extract the researchers added to the drink — a compound present in blueberries only in small amounts — so it is a large loss for one measured polyphenol and not for blueberry polyphenols as a class 4. How much blueberry anthocyanin or chlorogenic acid changes when banana and berries are blended together remains unmeasured, along with any effect on a health outcome 4. Her own answer is a personal preference: she keeps bananas out of the one drink where she is optimizing for polyphenols 5.
Q&A #85, and an oat trial she resurfaced
The October 9 members' Q&A is titled for two of its questions — how much sugar is too much, and whether supplements help in Parkinson's — and its published question list runs from urolithin A brands, creatine dosing, and postmenopausal protein and essential amino acids to microplastics in yogurt containers and oral-care products, raw versus pasteurized milk, and the temperature an infrared sauna needs to reach 17. The answers sit behind the members' paywall, so the public page gives the list; the free preview opens on sugar, where her point is that the source and the surrounding diet matter more than a single threshold 17.
Her October 9 post is about fiber. She describes a trial in which two days of a high-dose oat diet — 300 grams of rolled oats a day, about four cups — lowered LDL cholesterol by about 10% in adults with metabolic syndrome, while 80 grams a day for six weeks left it essentially unchanged 18. The trial appeared earlier: it was published in Nature Communications in January 2026, and she is resurfacing it 19. The design is the interesting part — a short, very high dose moved LDL where a longer, moderate one did not — and four cups of oats a day is a hard regimen to sustain.
Cross-expert check
Protein is the one subject on which two of the four landed in the same week. Blueprint's October 5 page puts a number on it — 1.2–1.6 grams per kilogram per day, with a plant-heavy tilt — and Rhonda Patrick's October 9 Q&A takes up complete protein and essential amino acids for postmenopausal women, one of the groups where the protein question is most contested 317. The two point the same way: a population analysis on one side, a listener's question about aging on the other. Her specific answer sits behind the members' paywall.
The week's other items stood alone. No second voice took up ER-100, the eye, blueberries, or the cholinesterase drugs, so there is no disagreement to weigh on those. One pattern does run through all four, and it is worth naming as a pattern rather than as agreement: each item reported an effect and then bounded it — two to three points against a three-to-four-point threshold, two of three patients with no control arm, a dose that worked at one cup and failed at half, a protein figure drawn from populations.
What to carry forward
- One cup of blueberries a day is the dose with human vascular evidence behind it; the half-cup dose left flow-mediated dilation unchanged in the six-month metabolic-syndrome trial 6.
- If you make a blueberry smoothie and care about polyphenols, leaving out the banana costs nothing; the measured interaction was on epicatechin from cocoa, and the blueberry-specific effect remains unmeasured 5.
- Judge cholinesterase inhibitors by their measured size: about 2–3 ADAS-Cog points at six months, near the 3–4-point mark for clinical importance, and mostly a matter of the untreated group declining 2.
- Protein intake of 1.2–1.6 grams per kilogram a day is the range both Blueprint and Patrick keep returning to; the evidence behind the longevity claim is observational 3.
- ER-100's readout is a safety result in three people, and the trial is now escalating to three times the dose; the next data point to watch is the higher-dose visual-field result 9.
- Pregnancy deserves reading as an early cardiometabolic stress test: a complication in pregnancy can flag a woman's risk of disease decades later, which is the thread in Attia's October 5 episode 1.
References
- 1#410 ‒ The biology of pregnancy, with Kathryn Gray
peterattiamd.com
- 2How much do symptomatic treatments for Alzheimer's disease help?
peterattiamd.com
- 3Protein for Longevity
blueprint.bryanjohnson.co
- 4The Science of Blueberries for Brain and Vascular Health
foundmyfitness.com
- 5
- 6Curtis et al., AJCN 2019
pubmed.ncbi.nlm.nih.gov
- 7
- 8Eyewire News on the ER-100 data
eyewire.news
- 9Lifespan Magazine on the ER-100 results
lifespan.com
- 10
- 11
- 12
- 13
- 14Bryan Johnson's Longevity Bowl Recipe
blueprint.bryanjohnson.co
- 15
- 16Devore et al., Annals of Neurology 2012
pmc.ncbi.nlm.nih.gov
- 17FoundMyFitness Q&A #85
foundmyfitness.com
- 18
- 19
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.